Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 262

Similar articles for PubMed (Select 17146740)

1.

Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.

Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M, Shibata D.

Ann Surg Oncol. 2007 Feb;14(2):780-5. Epub 2006 Dec 5.

PMID:
17146740
2.

Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.

Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK.

Ann Surg Oncol. 2006 Apr;13(4):572-81. Epub 2006 Feb 28. Erratum in: Ann Surg Oncol. 2006 Aug;13(8):1162. Strosberg, Jonathon [corrected to Strosberg, Jonathan].

PMID:
16511671
3.

Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report.

Søndenaa K, Sen J, Heinle F, Fjetland L, Gudlaugsson E, Syversen U.

World J Surg. 2004 Sep;28(9):890-5.

PMID:
15593463
4.

Hepatic surgery for metastases from neuroendocrine tumors.

Sarmiento JM, Que FG.

Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. Review.

PMID:
12735141
5.

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA.

Cancer J. 2003 Jul-Aug;9(4):261-7.

PMID:
12967136
6.

Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.

Nikou GC, Lygidakis NJ, Toubanakis C, Pavlatos S, Tseleni-Balafouta S, Giannatou E, Mallas E, Safioleas M.

Hepatogastroenterology. 2005 May-Jun;52(63):731-41.

PMID:
15966194
7.

The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.

Chambers AJ, Pasieka JL, Dixon E, Rorstad O.

Surgery. 2008 Oct;144(4):645-51; discussion 651-3. doi: 10.1016/j.surg.2008.06.008.

PMID:
18847650
8.
9.

Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.

Sartori P, Mussi C, Angelini C, Crippa S, Caprotti R, Uggeri F.

Langenbecks Arch Surg. 2005 Sep;390(5):391-6. Epub 2005 Jun 21.

PMID:
15968542
10.

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.

Ann Oncol. 2000 Sep;11(9):1127-30.

11.

Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors.

Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Akerström G, Hellman P.

World J Surg. 2008 May;32(5):930-8. doi: 10.1007/s00268-008-9510-3.

PMID:
18324347
12.

Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors.

Schell SR, Camp ER, Caridi JG, Hawkins IF Jr.

J Gastrointest Surg. 2002 Sep-Oct;6(5):664-70.

PMID:
12399054
13.

Cytoreductive hepatic surgery for neuroendocrine tumors.

McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS.

Surgery. 1990 Dec;108(6):1091-6.

PMID:
1701060
14.

Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience.

Gillams A, Cassoni A, Conway G, Lees W.

Abdom Imaging. 2005 Jul-Aug;30(4):435-41.

PMID:
15759207
15.

Cytoreductive surgery in patients with advanced-stage carcinoid tumors.

Gulec SA, Mountcastle TS, Frey D, Cundiff JD, Mathews E, Anthony L, O'Leary JP, Boudreaux JP.

Am Surg. 2002 Aug;68(8):667-71; discussion 671-2.

PMID:
12206599
16.

Survival and functional quality of life after resection for hepatic carcinoid metastasis.

Knox CD, Feurer ID, Wise PE, Lamps LW, Kelly Wright J, Chari RS, Lee Gorden D, Wright Pinson C.

J Gastrointest Surg. 2004 Sep-Oct;8(6):653-9.

PMID:
15358324
17.

Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.

Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S.

Ann Nucl Med. 2008 May;22(4):237-43. doi: 10.1007/s12149-007-0123-y. Epub 2008 Jun 6.

PMID:
18535873
18.

Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.

Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, Eriksson B, Janson ET.

Neuroendocrinology. 2009;89(3):302-7. doi: 10.1159/000179900. Epub 2009 Jan 29.

PMID:
19176944
19.

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.

Hellman P, Lundström T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, Tiensuu Janson E, Akerström G.

World J Surg. 2002 Aug;26(8):991-7. Epub 2002 May 21.

PMID:
12016480
20.

Surgical treatment of functioning metastatic carcinoid tumors.

Martin JK Jr, Moertel CG, Adson MA, Schutt AJ.

Arch Surg. 1983 May;118(5):537-42.

PMID:
6188438
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk